Outlook Therapeutics (OTLK) Income from Non-Controlling Interests (2015)

Outlook Therapeutics (OTLK) reported Income from Non-Controlling Interests of -$896136.0 for Q3 2015, down 135.56% quarter-over-quarter from -$380435.0 in Q2 2015.

Outlook Therapeutics (OTLK) Income from Non-Controlling Interests (2015) Analysis & Trends

Outlook Therapeutics (OTLK) has 1 years of Income from Non-Controlling Interests data on file, last reported at -$896136.0 in Q3 2015.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Alterity Therapeutics 719,706.53 Bn 719,706.50 Bn - -
2 Belite Bio 55,800.00 Bn 55,800.00 Bn - -
3 Quantum Biopharma 18,182.30 Bn 18,182.29 Bn - -13.75 Mn
4 Legend Biotech 3,154.00 Bn 3,153.71 Bn 242.10 Mn -
5 Akari Therapeutics 1,844.30 Bn 1,844.29 Bn - -
6 Evaxion A 1,567.96 Bn 1,567.94 Bn - -
7 Psyence Biomedical 251.43 Bn 251.42 Bn - -
8 Vertex Pharmaceuticals 112.56 Bn 105.31 Bn 2.59 Bn -
9 Abivax 94.37 Bn 94.37 Bn - -
10 Outlook Therapeutics 51.56 Mn 43.81 Mn -21,888.00 -

Historic Data

Download Data
DateValue
Sep 30, 2015 -896,136.00
Jun 30, 2015 -380,435.00